de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95(1):322–7. https://doi.org/10.1073/pnas.95.1.322.

Article  PubMed  PubMed Central  Google Scholar 

Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–85. https://doi.org/10.1016/s0092-8674(00)80949-6.

Article  CAS  PubMed  Google Scholar 

Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437–51. https://doi.org/10.1016/s0092-8674(00)81973-x.

Article  CAS  PubMed  Google Scholar 

Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365–76. https://doi.org/10.1016/s0092-8674(00)81965-0.

Article  CAS  PubMed  Google Scholar 

Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39–40.

Article  CAS  PubMed  Google Scholar 

Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains 124. NatMed. 2000;6(9):991–7.

CAS  Google Scholar 

Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–81. https://doi.org/10.1038/nrn2092.

Article  CAS  PubMed  Google Scholar 

Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle 234. J Neurosci. 2005;25(28):6716–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron. 2005;46(5):787–98. https://doi.org/10.1016/j.neuron.2005.04.035.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9(4):269–310. https://doi.org/10.1016/j.smrv.2005.03.004.

Article  PubMed  Google Scholar 

Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Curr Med Res Opin. 2016;32(10):1611–22. https://doi.org/10.1080/03007995.2016.1208643.

Article  CAS  PubMed  Google Scholar 

Riemann D, Espie CA, Altena E, Arnardottir ES, Baglioni C, Bassetti CLA, et al. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023. J Sleep Res. 2023;32(6):e14035. https://doi.org/10.1111/jsr.14035.

Article  PubMed  Google Scholar 

Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin sleep medicine: JCSM : official publication Am Acad Sleep Med. 2017;13(2):307–49. https://doi.org/10.5664/jcsm.6470.

Article  Google Scholar 

Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, et al. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry. 2016;79(2):136–48. https://doi.org/10.1016/j.biopsych.2014.10.003.

Article  CAS  PubMed  Google Scholar 

Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 2016;19:93–100. https://doi.org/10.1016/j.sleep.2015.10.007.

Article  PubMed  Google Scholar 

Moline M, Zammit G, Cheng JY, Perdomo C, Kumar D, Mayleben D. Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin sleep medicine: JCSM : official publication Am Acad Sleep Med. 2021;17(6):1167–74. https://doi.org/10.5664/jcsm.9150.

Article  Google Scholar 

Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw open. 2019;2(12):e1918254. https://doi.org/10.1001/jamanetworkopen.2019.18254.

Article  PubMed  PubMed Central  Google Scholar 

Karppa M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9). https://doi.org/10.1093/sleep/zsaa123.

Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–39. https://doi.org/10.1016/S1474-4422(21)00436-1.

Article  CAS  PubMed  Google Scholar 

Borbely A. The two-process model of sleep regulation: Beginnings and outlook. J Sleep Res. 2022;31(4):e13598. https://doi.org/10.1111/jsr.13598.

Article  PubMed  PubMed Central  Google Scholar 

Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003;54(2):96–104. https://doi.org/10.1016/s0006-3223(02)01740-7.

Article  CAS  PubMed  Google Scholar 

Grady SP, Nishino S, Czeisler CA, Hepner D, Scammell TE. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep. 2006;29(3):295–7. https://doi.org/10.1093/sleep/29.3.295.

Article  PubMed  Google Scholar 

Mogavero MP, Godos J, Grosso G, Caraci F, Ferri R. Rethinking the role of orexin in the regulation of REM sleep and appetite. Nutrients. 2023;15(17). https://doi.org/10.3390/nu15173679.

Saper CB, Cano G, Scammell TE. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol. 2005;493(1):92–8. https://doi.org/10.1002/cne.20770.

Article  CAS  PubMed  Google Scholar 

Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–62. https://doi.org/10.1001/archneur.59.10.1553.

Article  PubMed  Google Scholar 

Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A, et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018;562(7725):63–8. https://doi.org/10.1038/s41586-018-0540-1.

Article  CAS  PubMed  Google Scholar 

Pedersen NW, Holm A, Kristensen NP, Bjerregaard AM, Bentzen AK, Marquard AM, et al. CD8(+) T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat Commun. 2019;10(1):837. https://doi.org/10.1038/s41467-019-08774-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferri R, Pizza F, Vandi S, Iloti M, Plazzi G. Decreased sleep stage transition pattern complexity in narcolepsy type 1. Clin neurophysiology: official J Int Federation Clin Neurophysiol. 2016;127(8):2812–9. https://doi.org/10.1016/j.clinph.2016.05.364.

Article  Google Scholar 

Rauf R, Asif S, AlSaafeen A, Dhantapaani KG, Nadeem MM, Rao ZK, et al. Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers. Brain Behav. 2025;15(10):e70984. https://doi.org/10.1002/brb3.70984.

Article  CAS  PubMed  PubMed Central